Shepherd Street Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.51M Sell
3,168
-50
-2% -$22.2K 1.33% 26
2026
Q1
$1.44M Buy
3,218
+223
+7% +$104K 1.42% 26
2025
Q4
$1.36M Buy
+2,995
New +$1.29M 1.3% 27

Other funds holding VRTX

Shepherd Street Advisors's VRTX Position: Q2 2026 in Review

Shepherd Street Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 1.6% in Q2 2026, selling an estimated $22.2K and leaving 3,168 shares worth $1.51M. The position accounts for 1.33% of the portfolio, ranked #26.

Shepherd Street Advisors first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,752 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Shepherd Street Advisors held 3,168 shares of Vertex Pharmaceuticals worth $1.51M as of Q2 2026.
  • Shepherd Street Advisors sold 50 Vertex Pharmaceuticals shares in Q2 2026, an estimated $22.2K.
  • Vertex Pharmaceuticals made up 1.33% of Shepherd Street Advisors's portfolio in Q2 2026, its #26 holding.
  • Shepherd Street Advisors first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,752 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Shepherd Street Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.